Effect of LY293111 in combination with gemcitabine in colonic cancer

Cancer Letters

Volumn 210, Issue 1, 2004, Pages 41-46

  Hennig, Rene ^a   Ding, Xian Zhong ^a   Tong, Wei Gang ^a   Witt, Richard C ^a   Jovanovic, Borko D ^a   Adrian, Thomas E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Colon cancer; Gemcitabine; Heterotopic xenografts; LY293111

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; FATTY ACID; GEMCITABINE; LEUKOTRIENE; LINOLEIC ACID; LIPOXYGENASE; PROSTAGLANDIN SYNTHASE;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CELL LINE; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOIC ACIDS; BODY WEIGHT; COLONIC NEOPLASMS; DEOXYCYTIDINE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTORS, LEUKOTRIENE B4; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 2542469678     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.02.023     Document Type: Article

References (27)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics. CA Cancer J. Clin. 51:2001;15-36
2. Chau I., Cunningham D. Adjuvant therapy in colon cancer: current status and future directions. Cancer Treat. Rev. 28:2002;223-236
3. Nkondjock A., Shatenstein B., Maisonneuve P., Ghadirian P. Specific fatty acids and human colorectal cancer: an overview. Cancer Detect. Prev. 27:2003;55-66
4. Broitman S.A., Vitale J.J., Vavrousek-Jakuba E., Gottlieb L.S. Polyunsaturated fat, cholesterol and large bowel tumorigenesis. Cancer (Phila.). 40:1977;2455-2463
5. Singh J., Hamid R., Reddy B.S. Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res. 57:1997;3465-3470
6. Hussey H.J., Tisdale M.J. Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br. J. Cancer. 70:1994;6-10
7. Levy G.N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. Fed. Am. Soc. Exp. Biol. J. 11:1997;234-247
8. Thun M.J., Namboodiri M.M., Heath C.W. Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325:1991;1593-1596
9. Bortuzzo C., Hanif R., Kashfi K., Staiano-Coico L., Shiff S.J., Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim. Biophys. Acta. 1300:1996;240-246
10. Sampson A.P. The role of eosinophils and neutrophils in inflammation. Clin. Exp. Allergy. 30:(Suppl. 1):2000;22-27
11. Hennig R., Ding X.Z., Tong W.G., Schneider M.B., Standop J., Friess H., et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 161:2002;421-428
12. Tong W.G., Ding X.Z., Hennig R., Witt R.C., Standop J., Pour P.M., Adrian T.E. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin. Cancer Res. 8:2002;3232-3242
13. Earashi M., Noguchi M., Tanaka M. In vitro effects of eicosanoid synthesis inhibitors in the presence of linoleic acid on MDA-MB-231 human breast cancer cells. Breast Cancer Res. Treat. 37:1996;29-37
14. Okano-Mitani H., Ikai K., Imamura S. Human melanoma cells generate leukotrienes B4 and C4 from leukotriene A4. Arch. Dermatol. Res. 289:1997;347-351
15. Bittner S., Wielckens K. Glucocorticoid-induced lymphoma cell growth inhibition: the role of leukotriene B4. Endocrinology. 123:1988;991-1000
16. el Hakim I.E., Langdon J.D., Zakrzewski J.T., Costello J.F. Leukotriene B4 and oral cancer. Br. J. Oral Maxillofac. Surg. 28:1990;155-159
17. Kornmann M., Butzer U., Blatter J., Beger H.G., Link K.H. Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur. J. Surg. Oncol. 26:2000;583-587
18. Lawrence T.S., Chang E.Y., Hahn T.M., Shewach D.S. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′, 2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin. Cancer Res. 3:1997;777-782
19. Merriman R.L., Hertel L.W., Schultz R.M., Houghton P.J., Houghton J.A., Rutherford P.G., et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest. New Drugs. 14:1996;243-247
20. Rioux N., Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis (Lond.). 19:1998;1393-1400
21. Ghosh J., Myers C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl Acad. Sci. USA. 95:1998;13182-13187
22. Harris J.E., Alrefai W.A., Meng J., Anderson K.M. Five-lipoxygenase inhibitors reduce Panc-1 survival: synergism of MK886 with gamma linolenic acid. Adv. Exp. Med. Biol. 469:1999;505-510
23. Ding X.Z., Hennig R., Adrian T.E. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol. Cancer. 2:2003;10
24. Qiao L., Kozoni V., Tsioulias G.J., Koutsos M.I., Hanif R., Shiff S.J., Rigas B. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim. Biophys. Acta. 1258:1995;215-223
25. Carmichael J. The role of gemcitabine in the treatment of other tumours. Br. J. Cancer. 78:(Suppl. 3):1998;21-25
26. Tonkinson J.L., Worzalla J.F., Teng C.H., Mendelsohn L.G. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 59:1999;3671-3676
27. Semba S., Itoh N., Ito M., Harada M., Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin. Cancer Res. 8:2002;1957-1963